Latest Conference Articles

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what's to come as a result of a "second wave" of biosimilars hitting the market.

Technology and automation within patient assistance programs can enhance the patient journey and assist pharmaceutical manufacturers at a lower cost, explained Josh Marsh, vice president of Sonexus at Cardinal Health.

At the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, provided updates to the 2023 specialty therapy pipeline.

In a panel at the 2023 Asembia Specialty Pharmacy Summit, speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.

Reducing disparities in the treatment of atopic dermatitis (AD) was the focus of a session of the final day of the Revolutionizing Atopic Dermatitis 2023 conference.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).

Larry Eichenfield, MD, professor of dermatology and pediatrics and vice chair of the Department of Dermatology at the University of California San Diego School of Medicine and chief of pediatric and adolescent dermatology at Rady Children's Hospital San Diego, discusses the use of different treatments and biologics for atopic dermatitis (AD) in infants, which he presented at the Revolutionizing Atopic Dermatitis conference.

Panelists at the 2023 Asembia Specialty Pharmacy Summit discussed the myriad of ways that the drug pricing policies of the Inflation Reduction Act (IRA), such as inflation rebates and a redesign of Medicare Part D plans, will affect payers and manufacturers.

A panel held at Revolutionizing Atopic Dermatitis 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.

Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses treatment approaches for atopic dermatitis of the face in infancy, which he presented at the Revolutionizing Atopic Dermatitis conference.

Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.

In posters presented at the Revolutionizing Atopic Dermatitis conference, ruxolitinib cream was found to be both safe and effective in treating atopic dermatitis (AD).

Craig D. Pederson, principal at Insight Health Care Partners, discussed the evolving landscape of value-based care and challenges to implementation from the provider perspective during his keynote presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.

A session led by Irina Koyfman, DNP, NP-C, RN, at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023 detailed the potential of chronic care management billing for physicians who are not currently doing it and recommendations for optimizing the process.

Todd A. Zigrang, MBA, MHA, FACHE, CVA, ASA, ABV, president of Health Capital Consultants, discusses accountable care organizations (ACOs) and the move toward value-based care models.

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, discusses the importance of biomarker testing in non–small cell lung cancer (NSCLC).

In a presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023, Robert L. Waterhouse Jr, MD, MBA, HSM, chief medical officer at Baylor Scott & White Quality Alliance, discussed the challenges of value-based care implementation and how to overcome them.

Some of the health care transformations that were forced by the COVID-19 pandemic could continue to benefit patients and the health care system, Jacques Sokolov, MD, said during his keynote address at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.

Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center and professor of oncologic sciences at University of South Florida, discussed the shift to targeted therapies in acute myeloid leukemia (AML).

Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, talks about the importance of treating underlying sleep disorders in patients with seizures, especially within a value-based care (VBC) model.

Eric Lisle, president and CEO of Southeast Primary Care Partners, discusses the importance of comprehensive patient data for primary care practices implementing value-based care.

Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research and patch testing at the George Washington University School of Medicine and Health Sciences, and chair of the Revolutionizing Atopic Dermatitis (RAD) conference, discusses some of the symposia and events at this year's conference that he is looking forward to the most.

David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, talks about how an emerging epilepsy treatment could transform the current level of care for patients with the condition.

The Revolutionizing Atopic Dermatitis conference, set to begin on April 29 in Washington, DC, promises to offer symposia on emerging therapies and new insights into treating atopic dermatitis (AD).

The potential ethical implications for goals of care discussions between surrogate decision makers and health care providers concerning patients who reside in a state of cognitive motor dissociation were investigated in this new study from a team at Columbia University and New York Presbyterian Hospital.

Several presentations at the 2023 Asembia Specialty Pharmacy Summit, held in Las Vegas, Nevada, from April 30 through May 4, will cover how to address health equity concerns in specialty pharmacy care, the expansion of the biosimilars market, and the impact of the Inflation Reduction Act (IRA) on the US health care system.

Much more work needs to be done surrounding multiple sclerosis (MS) and treating pregnant patients safely, noted Mitzi Joi Williams, MD, FAAN, medical director and CEO, Joi Life Wellness Neurology Clinic.

Milena Pavlova, MD, neurologist and medical director of the sleep testing center at Brigham and Women’s Faulkner Hospital, discusses the profound effect obstructive sleep apnea has on epilepsy as well as cognition.

At Asembia 2023, there will be a call to action for participants to adjust their current business models and advocate for access to biosimilars with lower list costs, explained Julie Reed, executive director of the Biosimilars Forum.